Intrathecal Therapy for Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): An Updated Multicenter Analysis of Outcomes and Safety

Key Points

• ICANS therapy shows improved outcomes in patients with immune effector cell-related side effects, enhancing treatment benefits.
• The analysis includes data from multiple centers, indicating a broad spectrum of outcomes across different settings with varied patient responses.
• Assessment of safety outcomes reveals important insights into the risks associated with intrathecal therapy for ICANS treatment, informing clinical practice.
• These findings highlight the need for ongoing evaluation of treatment protocols to ensure the best possible patient care and safety.